Dextromethorphan received FDA approval in 1958 for its use as a cough suppressant. It is one of the most common compounds found in most over-the-counter antitussives for the past 50 years. In 2010, the FDA approved the use of dextromethorphan for pseudobulbar affect in combination with quinidine. This activity will highlight the mechanism of action, adverse event profile, approved and off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions of dextromethorphan, pertinent for members of the interprofessional team using dextromethorphan for any of its intended indications.

**Objectives:**
- Identify the mechanism of action of dextromethorphan.
- Outline the approved and other indications for therapy with dextromethorphan.
- Review the adverse event profile for dextromethorphan.
- Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients when using dextromethorphan.